Eukles Asset Management cut its position in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 0.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,726 shares of the medical research company’s stock after selling 77 shares during the quarter. Laboratory Corp. of America comprises about 2.2% of Eukles Asset Management’s holdings, making the stock its 11th largest position. Eukles Asset Management’s holdings in Laboratory Corp. of America were worth $2,546,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Laboratory Corp. of America by 2.6% in the first quarter. BlackRock Inc. now owns 10,029,286 shares of the medical research company’s stock worth $1,534,283,000 after purchasing an additional 257,173 shares during the period. FMR LLC grew its holdings in Laboratory Corp. of America by 81.4% in the first quarter. FMR LLC now owns 1,596,659 shares of the medical research company’s stock worth $244,257,000 after purchasing an additional 716,703 shares during the period. Dimensional Fund Advisors LP grew its holdings in Laboratory Corp. of America by 2.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,460,214 shares of the medical research company’s stock worth $184,501,000 after purchasing an additional 34,797 shares during the period. Geode Capital Management LLC grew its holdings in Laboratory Corp. of America by 8.6% in the fourth quarter. Geode Capital Management LLC now owns 1,412,093 shares of the medical research company’s stock worth $178,140,000 after purchasing an additional 111,859 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in Laboratory Corp. of America by 17.5% in the first quarter. Lazard Asset Management LLC now owns 1,137,166 shares of the medical research company’s stock worth $173,963,000 after purchasing an additional 169,233 shares during the period. Institutional investors own 90.78% of the company’s stock.

In related news, Director R Sanders Williams sold 500 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $162.91, for a total transaction of $81,455.00. Following the transaction, the director now directly owns 6,886 shares of the company’s stock, valued at $1,121,798.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Glenn A. Eisenberg sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $167.40, for a total transaction of $1,674,000.00. Following the sale, the chief financial officer now owns 28,366 shares of the company’s stock, valued at approximately $4,748,468.40. The disclosure for this sale can be found here. Insiders have sold 21,491 shares of company stock worth $3,677,189 over the last three months. 0.74% of the stock is owned by insiders.

Shares of LH traded down $0.09 during trading hours on Thursday, reaching $163.54. 11,345 shares of the stock traded hands, compared to its average volume of 793,047. The company has a current ratio of 1.12, a quick ratio of 1.03 and a debt-to-equity ratio of 0.95. The stock has a fifty day moving average price of $170.61. Laboratory Corp. of America Holdings has a 52 week low of $119.38 and a 52 week high of $182.75. The stock has a market cap of $16.01 billion, a P/E ratio of 14.81, a price-to-earnings-growth ratio of 1.50 and a beta of 1.05.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Thursday, July 25th. The medical research company reported $2.93 earnings per share for the quarter, beating analysts’ consensus estimates of $2.90 by $0.03. Laboratory Corp. of America had a net margin of 8.19% and a return on equity of 16.28%. The company had revenue of $2.88 billion for the quarter, compared to analyst estimates of $2.89 billion. During the same period last year, the firm earned $2.98 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. As a group, sell-side analysts expect that Laboratory Corp. of America Holdings will post 11.28 EPS for the current year.

A number of equities research analysts have commented on LH shares. ValuEngine upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a report on Wednesday, April 24th. TheStreet upgraded shares of Laboratory Corp. of America from a “c+” rating to a “b-” rating in a report on Friday, May 3rd. Canaccord Genuity raised their price target on shares of Laboratory Corp. of America from $155.00 to $165.00 and gave the stock a “hold” rating in a report on Thursday, May 2nd. Zacks Investment Research raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Thursday, May 16th. Finally, UBS Group raised their price objective on shares of Laboratory Corp. of America from $178.00 to $195.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $185.23.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Read More: Asset Allocation

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.